Atogepant, an investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist for migraine prevention, led to fewer monthly migraine days in episodic monthly migraine patients, results of a phase IIb/III trial showed here. Full story.
There is a significant unmet need for novel effective well‐tolerated acute migraine treatments. REN is a novel acute migraine treatment that stimulates upper arm peripheral nerves to induce conditioned pain modulation – an endogenous analgesic [...]
In research published online April 8 in the Journal of Neuroscience, the calcitonin gene-related peptide (CGRP) is implicated in the development of migraine symptoms caused pain responses in female rodents, but not in males, when [...]
Migraine is the second-most disabling disease worldwide, and the second most common neurological disorder. Attacks can last many hours or days, and consist of multiple symptoms including headache, nausea, vomiting, hypersensitivity to stimuli such as [...]
Read articles about the latest pain research present at AAPM35 in Denver, March 6-10, 2019. View articles.
© American Academy of Pain Medicine. All Rights Reserved | Privacy Policy | Media Resources
American Academy of Pain Medicine (AAPM) is a nonprofit 501(c)(6) tax-exempt organization.
